Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-04-03

Clinical Trial Update: Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Wharton’s Jelly–derived mesenchymal stromal cells for adults with Type 1 diabetes; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Wharton’s jelly-derived mesenchymal stromal cells (Wharton’s jelly-derived mesenchymal stromal cells)

Snippet

Sponsor: NextCell Pharma Ab | Conditions: Type1 Diabetes Mellitus | Phase 1, Phase 2 | Status: COMPLETED